Derivation of utility values from EORTC QLQC30 in lung cancer

被引：2
|
作者：
Jang, R. W.
Mittmann, N. [2 ]
Isogai, P. [2 ]
Bradbury, P. A. [1 ]
Leighl, N. B.
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] HOPE Res Ctr, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70254-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A77 / A78
页数：2
相关论文
共 50 条
  • [41] PSYCHOMETRIC EVALUATION OF EORTC QLQ-C30 IN CUBAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Viada Gonzalez, C.
    Bouza, C. N.
    Fors, M. M.
    Frias, A.
    Alvarez, M.
    Garcia, L.
    Wilkinson, B.
    Rodriguez, P. C.
    Crombet, T.
    Ballesteros, J.
    VALUE IN HEALTH, 2018, 21 : S391 - S391
  • [42] A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.
    Chan, Kelvin K.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Au, Heather-Jane
    Leighl, Natasha B.
    Brundage, Michael Donald
    Jonker, Derek J.
    Karapetis, Christos Stelios
    Ringash, Jolie
    Zalcberg, John Raymond
    Hoch, Jeffrey S.
    Tebbutt, Niall C.
    Shapiro, Jeremy
    Price, Timothy Jay
    Pavlakis, Nick
    Van Hazel, Guy A.
    Mittmann, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [43] IMPACT OF TREATMENT WITH ERIBULIN (ERI) OR CAPECITABINE (CAP) FOR METASTATIC BREAST CANCER (MBC) ON EQ-5D UTILITY DERIVED FROM EORTC QLQ-C30
    Hudgens, S.
    Briggs, A.
    Velikova, G.
    Forsythe, A.
    McCutcheon, S.
    Kind, P.
    ANNALS OF ONCOLOGY, 2014, 25
  • [44] Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets
    Simone Seyringer
    Micha J. Pilz
    Imad Al-Naesan
    Madeleine T. King
    Andrew Bottomley
    Richard Norman
    Lisa Schlosser
    Tobias Hell
    Eva M. Gamper
    Scientific Reports, 15 (1)
  • [45] Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial.
    Kindler, Hedy L.
    Amin, Suvina
    Joo, Seongjung
    Patel, Nikunj
    Yoo, Hyun Kyoo
    Johnson, Colin
    Byrnes, Hilary
    Costa-Cabral, Sara
    Nolte, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [46] Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values
    van Gelder, Thomas
    Mulhern, Brendan
    Schoormans, Dounya
    Husson, Olga
    Lourenco, Richard de Abreu
    QUALITY OF LIFE RESEARCH, 2020, 29 (06) : 1483 - 1494
  • [47] Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values
    Thomas van Gelder
    Brendan Mulhern
    Dounya Schoormans
    Olga Husson
    Richard De Abreu Lourenço
    Quality of Life Research, 2020, 29 : 1483 - 1494
  • [48] Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
    Carmen Viada
    Carlos Bouza
    Martha Fors
    Aliuska Frías
    Mabel Alvarez
    Lázara García
    Bárbara Wilkinson
    Camilo Rodríguez
    Tania Crombet
    Javier Ballesteros
    Quality of Life Research, 2020, 29 : 3441 - 3448
  • [49] Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
    Viada, Carmen
    Bouza, Carlos
    Fors, Martha
    Frias, Aliuska
    Alvarez, Mabel
    Garcia, Lazara
    Wilkinson, Barbara
    Rodriguez, Camilo
    Crombet, Tania
    Ballesteros, Javier
    QUALITY OF LIFE RESEARCH, 2020, 29 (12) : 3441 - 3448
  • [50] An EORTC QLQ-C30-based instrument for the evaluation of the perceived impact of out-patient management of advanced lung cancer
    Cortese, C
    Martignetti, A
    Tagliaferri, P
    Giannicola, R
    Perricelli, A
    Salvino, A
    Barbieri, V
    Tassone, P
    Prantera, T
    Venuta, S
    ANNALS OF ONCOLOGY, 2000, 11 : 78 - 78
12345